Syngene International Limited — Important, 23-01-2025: Updates

The Board of Directors of Syngene International Limited has approved an amendment to the company's Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information. This update is intended to enhance the company's approach to fair disclosure practices, in alignment with regulatory requirements. The revised code will be accessible on the company's website, reflecting its commitment to transparency and compliance. This strategic move underscores Syngene's proactive stance on corporate governance and could positively influence investor confidence and stakeholder relations as the company continues to navigate the competitive landscape of the biopharmaceutical industry.